{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"14"}]}],"title":"At least one SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"}]}],"title":"At least one treatment related SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"35"}],"units":"Participants"}],"description":"Qualitative and quantitative toxicities assessed by incidence of adverse events and by clinically significant changes in the patient's physical examination, vital signs, and clinical laboratory results.\n\nThe incidence of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs).","groups":[{"description":"40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG000","title":"BT062 40 mg/m²"},{"description":"50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG001","title":"BT062 50 mg/m²"},{"description":"65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG002","title":"BT062 65 mg/m²"},{"description":"80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG003","title":"BT062 80 mg/m²"},{"description":"100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG004","title":"BT062 100 mg/m²"},{"description":"120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG005","title":"BT062 120 mg/m²"},{"description":"140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG006","title":"BT062 140 mg/m²"},{"description":"160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG007","title":"BT062 160 mg/m²"},{"description":"BT062 Administration (all dose levels)","id":"OG008","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: The Safety population included all subjects who were enrolled and received at least 1 dose of BT062 (n = 35).","reportingStatus":"POSTED","timeFrame":"Starting with first study drug administration until 30-day follow-up visit (average 4.99 months)","title":"Qualitative and Quantitative Toxicities of BT062","type":"SECONDARY","unitOfMeasure":"Participants"}